VKTX’s Non-Obesity Pipeline Shows Potential Apart from VK2735, Viking is also developing drugs targeting non-alcoholic steatohepatitis (NASH) and X-linked adrenoleukodystrophy (X-ALD ...

Shares of Viking Therapeutics VKTX lost 18% yesterday after pharma ... another company developing a potential obesity drug, also plummeted 11% post Merck’s announcement. Year to date, Viking ...

Viking Therapeutics Inc.’s stock jumped 3% Tuesday, after a bullish note from Oppenheimer highlighted the company’s promising ...

When the company reported VK2735's phase 2 results last year, the stock jumped 121% in one trading session. Viking gave back ...

VKTX’s shares are currently trading below the 50 and 200-day moving averages. Though this biotech’s progress with its obesity drug has been encouraging, the rising competition for developing ...

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

Jefferies analyst Roger Song maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...

Popular obesity stocks fell on Tuesday after pharma giant Eli Lilly LLY lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers.

Shares of Viking Therapeutics VKTX lost 18% yesterday after pharma giant Merck MRK announced its foray into the obesity space. On Wednesday, Merck announced that it has secured a licensing deal for ...

VKTX’s shares are currently trading below the 50 and 200-day moving averages. Though this biotech’s progress with its obesity drug has been encouraging, the rising competition for developing obesity ...